Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 7.1% – Here’s What Happened

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares traded down 7.1% during mid-day trading on Tuesday . The stock traded as low as $0.24 and last traded at $0.24. 19,377,092 shares were traded during mid-day trading, a decline of 70% from the average session volume of 64,156,387 shares. The stock had previously closed at $0.26.

Analyst Ratings Changes

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a report on Thursday, January 9th. They set a “hold” rating on the stock.

Tonix Pharmaceuticals Stock Performance

The company has a market capitalization of $43.92 million, a price-to-earnings ratio of 0.00 and a beta of 2.02. The company has a 50 day moving average price of $0.26 and a 200 day moving average price of $0.31. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Equities research analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.